Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial

Publication | Closed Access

DOI

202

Citations

References

2019

Year

Hiromichi Hamada, Hiroyuki Suzuki, Yoshihiro Onouchi, Ryota Ebata, Masaru Terai, Shigeto Fuse, Yoshitomo Okajima, Shunji Kurotobi, Katsuki Hirai, Takashi Soga,

The Lancet

Cardiovascular DiseaseAtherosclerosisIntravenous ImmunoglobulinImmunologyMedicineKawasaki DiseaseCardiologyCoronary Artery DiseaseCoronary Artery AbnormalitiesCardiovascular Translational Research